Cancerimmunterapi til behandling af hæmatologisk cancer

Translated title of the contribution: Cancer immune therapy for the treatment of haematological malignancies

Morten Orebo Holmström, Uffe Klausen, Nicolai Grønne Jørgensen, Staffan Holmberg, Jacob Grauslund, Özcan Met, Inge Marie Svane, Lars Møller Pedersen, Lene Meldgaard Knudsen, Hans Carl Hasselbalch, Mads Hald Andersen


Cancer immune therapy is now used routinely for the treatment of several solid malignancies, albeit just recently having entered the clinic for treatment of haematological malignancies. Several studies demonstrate that cancer immune therapy is a promising treatment modality for the latter. Especially treatment with chimeric antigen receptor T cells for acute lymphoblastic leukaemia and lymphoma is promising. Other promising treatment modalities are immune check point inhibitors for both lymphoid and myeloid malignancies, as well as therapeutic cancer vaccination targeting tumour antigens.

Translated title of the contributionCancer immune therapy for the treatment of haematological malignancies
Original languageDanish
JournalUgeskrift for Laeger
Issue number10
Publication statusPublished - 4 Mar 2019


Dive into the research topics of 'Cancer immune therapy for the treatment of haematological malignancies'. Together they form a unique fingerprint.

Cite this